Compare CVS Health Corp (CVS) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Microsoft — how do they compare? CVS Health Corp trades at $104.86 (market cap $135.48B), while Microsoft trades at $386.4 (market cap $2.86T). The key difference: Microsoft is far larger — about 21.1× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | MSFT | |
|---|---|---|
Market Cap | $135.48B | $2.86T |
Sector | Health | Technology |
52-Week High | $106.18 | $542.07 |
52-Week Low | $58.75 | $352.83 |
Enterprise Value | $202.02B | $2.84T |
Dividend Yield | 2.51% | 0.95% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Microsoft (MSFT) trades at $390.99, up 1.53% today, with a neutral technical signal and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth remains robust at $281.72B for 2025, supported by 68.31% gross margins and $136.16B in operating cash flow. Analyst consensus is overwhelmingly bullish with 80.49% buy ratings and a $552.81 price target, representing 41% upside potential from current levels.
Microsoft's AI leadership and cloud momentum position it for continued growth, though elevated capital expenditures and competitive pressures present near-term headwinds. The stock's current valuation at 23.29 P/E appears reasonable given the company's strong profitability and growth trajectory. Institutional ownership remains substantial, with recent news highlighting Azure's strength and Copilot adoption as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
